Aurobindo Pharma has received final USFDA approval for its generic Perampanel tablets, used to treat epilepsy. The product, which is bioequivalent to Catalyst Pharmaceuticals' Fycompa, targets a US market segment valued at approximately US$ 67 million. The company expects to launch the medication in the third quarter of fiscal year 2027, further strengthening its extensive US generic portfolio which now stands at 599 total approvals.
Aurobindo Pharma Receives USFDA Approval for Perampanel Tablets
US$ 67 million annual addressable market size.
599 total cumulative USFDA ANDA approvals for the company.
Reader Takeaway: New generic approval expands US neurology portfolio; launch set for Q3FY27 pending market competition dynamics.
What just happened
Aurobindo Pharma has secured final approval from the US Food and Drug Administration (USFDA) to manufacture and market Perampanel Tablets in strengths ranging from 2 mg to 12 mg. The tablets are generic equivalents to Catalyst Pharmaceuticals' Fycompa, a medication prescribed for various seizure disorders. The manufacturing will be handled at the company's Unit-IV facility under its subsidiary, APL Healthcare.
Why this matters
This approval allows Aurobindo to participate in a US market valued at US$ 67 million based on data for the year ending August 2026. By adding another specialized product to its US catalog, the firm continues to execute its strategy of scaling its generic drug presence in North America. The product is indicated for partial-onset seizures in patients four years and older, as well as adjunctive therapy for primary generalized tonic-clonic seizures in patients 12 and older.
The backstory
Aurobindo Pharma has steadily built one of the largest generic portfolios in the industry. With this recent certification, the company now holds 599 Abbreviated New Drug Application (ANDA) approvals from the US regulator, consisting of 574 final approvals and 25 tentative ones. This consistency in regulatory clearance remains a core pillar of the company's export-led business model.
What changes now
The company has scheduled the commercial launch of these tablets for the third quarter of fiscal year 2027. Investors will watch for the competitive landscape at the time of launch, as the arrival of generic versions often prompts pricing adjustments in the US market.
What to track next
Shareholders should monitor the Q3FY27 earnings calls for updates on the product rollout and potential revenue impact from the Perampanel range as it begins to contribute to the US top-line.